<DOC>
	<DOC>NCT01213017</DOC>
	<brief_summary>The purpose of this study is to determine whether Certolizumab pegol can rapidly reduce the inflammatory changes and inhibit erosions on hand and wrist MRI in patients with active moderate to severe rheumatoid arthritis.</brief_summary>
	<brief_title>The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients</brief_title>
	<detailed_description>The primary objective of this Phase IIIb, two-center, open-label study is to evaluate the efficacy of Certolizumab pegol in reducing synovitis and bone edema by evaluating change from baseline in synovitis and bone edema MRI scores at week 6 in patients with moderate to severe rheumatoid arthritis.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Synovitis</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>moderate to severe RA (DAS &gt; 4.4) at least two swollen and tender joints in one of the hand/ wrist patients must have failed at least one nonbiologic or biologic DMARDs currently receiving MTX therapy concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Certolizumab pegol</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>RAPID 3</keyword>
</DOC>